Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278619 | 0.81 | MAPT (0.41) | ALDH1A1 | |
| SCHEMBL4272313 | 0.73 | KCNH2 (0.38) | ALDH1A1SIGMAR1 | |
| SCHEMBL4273459 | 0.71 | ALDH1A1 (0.47) | ALDH1A1HTR2AHTR2CHTR2BADRB1 | |
| SCHEMBL27470601 | 0.68 | ALDH1A1 (0.35) | ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL4269522 | 0.66 | CYP19A1 (0.36) | ALDH1A1 | |
| SCHEMBL4272315 | 0.66 | ALDH1A1 (0.36) | ALDH1A1HTR2AHTR2CHTR1ADRD2 | |
| SCHEMBL4275694 | 0.66 | ALDH1A1 (0.42) | ALDH1A1HTR2AHTR2CHTR2BADRB1 | |
| SCHEMBL4274285 | 0.65 | CYP19A1 (0.33) | — | |
| SCHEMBL4265391 | 0.65 | CYP19A1 (0.33) | — | |
| SCHEMBL4275369 | 0.62 | CYP19A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605183-B2 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2009-10-20 | — | — | US | disclosed |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | KOYAMA SHOZO | 2008-08-21 | — | — | US | disclosed |
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2007-03-22 | — | — | US | disclosed |
| EP-0780122-B1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | KOYAMA SHOZO (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6710090-B2 | A CYCLOHEX-1-EN-2-ONE COMPOUND | KOYAMA SHOZO (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6346551-B1 | ANTIBACTERIAL, ANTIFUNGAL, ANTIVIRAL, BACTERICIDAL AND/OR STERILIZATION AGENTS, ANTICANCER DRUGS, BLOOD COAGULATION AND FIBRINOLYSIS INHIBITORS AND/OR BLOCKING AGENTS, INHIBITORY AND/OR BLOCKING AGENTS OF ANTIGEN-ANTIBODY REACTIONS | KOYAMA SHOZO (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0780122-A1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | Koyama, Shozo (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, SERPINB6, CD74 | ALDH1A1 1104/4885HTR2A 3577/4885HTR2C 4316/4885 |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD69, TFPI, SERPINE1 | ALDH1A1 2177/4885HTR2A 3198/4885HTR2C 4281/4885 |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, MCL1, CD74 | ALDH1A1 595/4885HTR2A 3616/4885HTR2C 4285/4885 |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | CD47, MCL1, BAK1 | ALDH1A1 1294/4885HTR2A 3659/4885HTR2C 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.